Zim Laboratories Ltd. (IN:ZIMLAB)
:ZIMLAB
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹126.95
Previous CloseN/A
Volume52.11K
Average Volume (3M)6.28K
Market Cap
₹3.25B
Enterprise Value₹4.46B
Total Cash (Recent Filing)₹50.12M
Total Debt (Recent Filing)₹1.23B
Price to Earnings (P/E)20.0
Beta1.09
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.90
Shares Outstanding48,735,813
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.62
Price to Sales (P/S)1.09
P/FCF Ratio1.15K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operational Efficiency And MarginsImproved gross margins and stable EBIT/EBITDA margins point to a durable operating model that can sustain profitability through cost control and scale. Over 2-6 months this supports resilience to pricing pressure, preserves operating cash, and enables reinvestment in manufacturing capabilities.
Improving Operating Cash FlowStronger operating cash flow provides a persistent liquidity buffer that funds working capital and routine capex without immediate external funding. This enhances financial flexibility for manufacturing scale-up, regulatory compliance costs, and sustaining contract-manufacturing commitments.
Healthy Equity PositionAn improving equity ratio strengthens balance-sheet resilience and borrowing capacity, reducing solvency risk in a regulated pharma business. This structural balance supports strategic investments, potential partnerships, and the ability to withstand short-term revenue volatility over the coming months.
Bears Say
Declining Net Profit MarginA falling net profit margin erodes retained earnings and long-term return on equity, limiting internal funding for R&D or expansion. If persistent, margin compression can weaken competitive positioning in generics and constrain management's ability to invest in drug-delivery platforms.
Low Free Cash FlowLow free cash flow reduces capacity to deleverage, pay dividends, or fund organic growth without new financing. Sustained high capex absorbtion can limit strategic agility and increase dependence on debt or equity raises, which is a structural constraint for mid-term expansion plans.
Rising LeverageIncremental leverage raises interest and refinancing risk and narrows financial flexibility. In a sector facing regulatory and market unpredictability, higher debt levels could amplify earnings volatility and limit capacity to invest in product approvals or new manufacturing lines.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹126.95 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹3.25B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is May 14, 2026 which is in 38 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on Feb 11, 2026. The company reported ₹0.902 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.902.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 48,735,813 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of ₹0.902 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.719%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.
Technical Analysis
Albert David Ltd
―
Lyka Labs Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―